56. Eur J Clin Pharmacol. 2018 Sep;74(9):1181-1184. doi: 10.1007/s00228-018-2496-3.Epub 2018 Jun 3.Tamoxifen and the risk of Parkinsonism: a case/non-case study.Montastruc F(1)(2)(3)(4), Khosrow-Khavar F(5)(6), de Germay S(1)(2)(7), RenouxC(5)(6)(8), Rousseau V(2)(3)(4)(7), Durrieu G(2)(3), Montastruc M(9), RascolO(1)(2)(4)(10), Sommet A(1)(2)(4)(7)(10), Lapeyre-Mestre M(1)(2)(4)(7)(10),Benevent J(1)(2)(3)(7), Montastruc JL(11)(12)(13)(14)(15)(16).Author information: (1)Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine,Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France.(2)Service de Pharmacologie Médicale et Clinique, Centre HospitalierUniversitaire de Toulouse, Toulouse, France.(3)Centre Régional de PharmacoVigilance, de Pharmacoépidémiologie etd'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse,Toulouse, France.(4)NeuroToul Centre of Excellence in Neurodegeneration, Centre HospitalierUniversitaire de Toulouse, Toulouse, France.(5)Centre for Clinical Epidemiology, Lady Davis Institute, Jewish GeneralHospital, Montreal, Québec, Canada.(6)Department of Epidemiology, Biostatistics, and Occupational Health, McGillUniversity, Montreal, Québec, Canada.(7)INSERM UMR 1027, Faculté de Médecine de Toulouse, Université de Toulouse,Toulouse, France.(8)Department of Neurology and Neurosurgery, McGill University, Montreal, Québec,Canada.(9)Institut Universitaire du Cancer Toulouse-Oncopôle, 1 avenueIrène-Joliot-Curie, 31059, Toulouse, France.(10)CIC INSERM 1436, Centre Hospitalier Universitaire de Toulouse, Université de Toulouse, Toulouse, France.(11)Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine,Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France.jean-louis.montastruc@univ-tlse3.fr.(12)Service de Pharmacologie Médicale et Clinique, Centre HospitalierUniversitaire de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.(13)Centre Régional de PharmacoVigilance, de Pharmacoépidémiologie etd'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse,Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.(14)NeuroToul Centre of Excellence in Neurodegeneration, Centre HospitalierUniversitaire de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.(15)INSERM UMR 1027, Faculté de Médecine de Toulouse, Université de Toulouse,Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.(16)CIC INSERM 1436, Centre Hospitalier Universitaire de Toulouse, Université de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.BACKGROUND: Three studies have suggested a potential positive association betweenthe use of tamoxifen in breast cancer and Parkinsonism, mainly after long-termexposure.OBJECTIVES: To explore this potential signal, we performed a case/non-case study using the World Health Organization Global Individual Case Safety Reports (ICSRs)database, VigiBase® between 1979 and 2018.METHODS: Among women ≥ 55 years, we measured the risk of reporting "Parkinsonism"compared with all other adverse drug reactions [as a reporting odds ratio (ROR95% CI)] for tamoxifen compared to all other drugs or aromatase inhibitors.RESULTS: During the study period, 356 ICSRs of Parkinsonism reported withtamoxifen were identified. We failed to find a positive association betweentamoxifen exposure and Parkinsonism in comparison with exposure to other drugs(ROR = 0.79; 95% CI 0.71-0.88) or aromatase inhibitors (ROR = 0.39; 95% CI0.33-0.46).CONCLUSION: This study did not find evidence for Parkinsonism associated withtamoxifen.DOI: 10.1007/s00228-018-2496-3 PMID: 29862427 